69 Views | 35 Downloads
David H. Munn, MD, Professor of Pediatric Oncology, Pediatric Immunotherapy Program, Georgia Cancer Center, Room CN-4141, Medical College of Georgia, Augusta University, 1120 Fifteenth St. , Augusta, GA 30912, Tel. 706.721.7141 | Fax 706.721.4804. Email: dmunn@augusta.edu
Madhav D. Sharma – designed and conducted experiments Rafal Pacholczyk – analyzed scRNA-seq data for mouse cells; performed UMAP analysis of published human scRNA-seq datasets; analyzed kynurenine assays Huidong Shi – performed and analyzed ATAC-seq assays and mouse bulk RNA-seq Zuzana Berrong – performed kynurenine assays Yousef Zakharia – provided clinical samples and reviewed and discussed the manuscript Austin Greco – provided clinical samples Chang-Sheng S. Chang – performed analysis of scRNA-seq for mouse cells Sudharshan Eathiraj – provided reagents and reviewed and discussed the manuscript Eugene Kennedy – provided reagents and reviewed and discussed the manuscript Thomas Cash – provided clinical samples and reviewed and discussed the manuscript Roni Bollag – provided clinical samples and reviewed and discussed the manuscript Ravindra Kolhe – provided clinical samples and reviewed and discussed the manuscript Ramses Sadek – biostatistician Tracy McGaha – helped conceptualize experiments and reviewed and discussed the manuscript Paulo Rodriguez – helped conceptualize experiments and reviewed and discussed the manuscript Bruce R. Blazar – helped conceptualize experiments and reviewed and discussed the manuscript Theodore S. Johnson – helped conceptualize experiments and reviewed and discussed the manuscript David H. Munn – designed the experiments, analyzed data, made the figures, wrote the manuscript, lead contact and corresponding author
The authors thank Anita Sharma, Joyce Wilson and Gabriela Pacholczyk for expert technical assistance; Jeanene Pihkala and the Cancer Center Flow Cytometry Core for cell-sorting; Eiko Kitamura and the Cancer Center Integrated Genomics Core for single-cell sequencing; and Dr. S. Chen, Rutgers University, for the gift of Tg(Grm1)Epv mice. Supported by NIH R01CA103320 and R01CA211229 to D.H.M.; R50CA232983 to M.D.S.; R01HL56067 and R01HL11879 to B.R.B.; and support from the Press-On Foundation and the Beloco Foundation to D.H.M. and T.S.J.
Y.Z. has received clinical trial support from NewLink Genetics (now Lumos Pharma). S. E. was an employee of ArQule, Inc. (now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA), which holds the rights to ArQ531. E.K. was an employee of NewLink Genetics (now Lumos Pharma). T.L.M. receives consulting income from FLX Therapeutics. B.R.B. holds intellectual property interests in the therapeutic use of IDO inhibitors; receives remuneration as an advisor to Magenta Therapeutics and BlueRock Therapeutics; receives research funding from BlueRock Therapeutics, Rheos Medicines, and Equilibre Biopharmaceuticals Corp. T.S.J. has received clinical trial funding from NewLink Genetics (now Lumos Pharma). D.H.M. (corresponding author) holds patents and intellectual property interests in the therapeutic use of IDO inhibitors; and has received consulting income and research support from NewLink Genetics (now Lumos Pharma). The other authors declare no competing interests.